Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Basilea (SIX: BSLN) secures a US$30m Cresemba milestone payment >

Arron Aatkar, PhD | Healthcare | Comment | 3 days ago

SynAct Pharma (STO: SYNACT) confirms recruitment on-track in RA trial >

Arron Aatkar, PhD | Healthcare | Comment | 3 days ago

SEE ALL COMMENTARY >

KALA BIO (KALA)

Latest price

USD0.76

▾ 0.01 (1.33)

As at 06/11/2025

Market capitalisation: USD6m

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: Small modular reactors – why governments and tech giants are embracing SMRs

Digital assets: Unlocking opportunities in listed blockchain equities

Hybrid Air Vehicles – Military options advance

Audiovisual

Latest

The Biotech Growth Trust Webinar: Brightening Prospects for Biotechs

Uncovering Trusts – BlackRock Latin American Investment Trust (BRLA): Volatility can provide compelling opportunities

The Diverse Income Trust in 60 seconds

About Edison

About Edison

Careers

Healthcare Equities

KALA BIO (KALA)

USD0.76

LTR Pharma (LTP)

AUD0.43

LTR Pharma — Sizable upside potential for intranasal delivery

See morecontent on

Medigene (MDG1)

EUR0.13

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Bull, Bear & Beyond – Medigene: executive interview

Medigene – executive interview

See morecontent on

Mendus (IMMU)

SEK6.90

Mendus – executive interview

Mendus — New strategy to include CML alongside AML

Mendus — Steady progress throughout Q225

See morecontent on

Newron Pharmaceuticals (NWRN)

CHF14.38

Newron Pharmaceuticals — H125 results reflect evenamide progress

Newron Pharmaceuticals — ENIGMA-TRS 1 commences enrolment

Newron Pharmaceuticals — Evenamide enters ENIGMA-TRS programme

See morecontent on

Nykode Therapeutics (NYKD)

NOK2.75

Nykode Therapeutics — Repositioned to streamline clinical progress

See morecontent on

Ocugen (OCGN)

USD1.41

Ocugen — Novel cell therapies for retinal diseases

See morecontent on

Okyo Pharma (OKYO)

USD2.63

Okyo Pharma — Targeting underserved corneal diseases

See morecontent on

Oncopeptides (ONCO)

SEK4.78

Oncopeptides — Targeted oncology with commercial momentum

See morecontent on

OpGen (OPGN)

—

OpGen — Cash concerns dampen active Q2

OpGen — FIND collaboration advances to development

OpGen — Feasibility milestone from FIND collaboration

See morecontent on

Oryzon Genomics (ORY)

EUR3.36

Oryzon Genomics — Progress for iadademstat across the board

Oryzon Genomics — Making headway towards Phase III in BPD

Oryzon Genomics — Foray into sickle cell disease

See morecontent on

OSE Immunotherapeutics (OSE)

EUR5.36

OSE Immunotherapeutics — Refocusing for the next phase

OSE Immunotherapeutics — Updated cash position; new collaboration

OSE Immunotherapeutics – executive interview

See morecontent on

Percheron Therapeutics (PER)

AUD0.01

Percheron Therapeutics — Positive Phase I readout strengthens outlook

Percheron Therapeutics — Resetting the narrative with a VISTA focus

Percheron Therapeutics – executive interview

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on